Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Veru Files Emergency Use Application For Its COVID-19 Treatment
Veru Inc VERU has submitted an emergency use authorization application to the FDA for the use of sabizabulin for COVID-19 treatment.
The application covers moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome.
Shares are up 3.98% at $14.11 during the premarket session.
Delcath Systems Eye Cancer Trial Data Update At ASCO Meeting
Delcath Systems Inc DCTH announced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system.
The CHOPIN trial assessed ipilimumab plus nivolumab (IPI+NIVO) combined with Delcath's proprietary liver-targeted PHP treatment in metastatic uveal melanoma patients.
The poster reports a Best Overall Response of 1 complete response, five partial responses, and one stable disease accounting for an Objective Response Rate of 85.7%.
Adverum's CFO Resigns
Adverum Biotechnologies Inc's ADVM CFO Rupert D'Souza, advised the company that he was resigning, effective immediately.
John Rakow, General Counsel of Adverum, became senior vice president and acting CFO.
Vincerx Streamlines, Realigns Resources
Vincerx Pharma Inc VINC is prioritizing Phase 1b VIP152 studies to focus on double-hit diffuse large B-cell lymphoma and chronic lymphocytic leukemia.
The company will continue to advance the next-generation modular bioconjugation platform. IND filings for VIP236 in 2H22 and VIP943 in 2H23 remain on track.
Vincerx will cut 33% of its workforce. Streamlining and realigning resources will extend the estimated cash runway into late 2024.
Kiromic Stock Surges On Research Pact For Gamma Delta T cell Product Pipeline
Kiromic BioPharma Inc KRBP has entered into a two-year sponsored research agreement (SRA) with Principal Investigator James Welsh of The University of Texas MD Anderson Cancer Center.
In vivo preclinical data will be generated from Kiromic's Gamma Delta T cell allogeneic therapies.
This SRA will evaluate efficacy and patient safety outcomes to support three new investigational drug applications (for Procel, Isocel, and Deltacel) to the FDA.
Shares are surging 159% at 73 cents during the premarket trading.
Immatics, Editas Medicine Ink Cancer Therapy Pact
Immatics N.V. IMTX and Editas Medicine Inc EDIT have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing cancer therapies.
Immatics gains non-exclusive rights to Editas Medicine's CRISPR technology and intellectual property as part of the licensing agreement.
Specific deal terms were not disclosed.
Moderna Starts Dosing In Flu Vaccine Study
Moderna Inc MRNA has dosed the first participants in a Phase 3 study of its seasonal influenza vaccine candidate (mRNA-1010).
The trial is expected to enroll approximately 6,000 adults in Southern Hemisphere countries.
The Phase 3 randomized, observer-blind study evaluates the safety and immunological non-inferiority of mRNA-1010 as a licensed seasonal influenza vaccine in adults.
Ginkgo Bioworks, Novo Nordisk Collaborate For Expression Hosts For Pharmaceutical Products
Ginkgo Bioworks Holdings Inc DNA has collaborated with Novo Nordisk A/S NVO to unlock the potential of expression systems, which may accelerate and enhance the discovery and development of Novo Nordisk's biological medicines.
Under the terms of the partnership, Ginkgo and Novo Nordisk will launch a multi-year collaboration. Ginkgo will receive an upfront R&D fee and is eligible to receive milestone payments.
American Society of Clinical Oncology (ASCO) Presentations
PDS Biotechnology Corp PDSB: Preliminary Phase 2 results of PDS0101 and pembrolizumab combo in recurrent or metastatic head and neck cancer.
Elevation Oncology Inc ELEV: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.
Jazz Pharmaceuticals plc JAZZ: Efficacy and safety of intramuscular recombinant Erwinia asparaginase in acute lymphoblastic leukemia or lymphoblastic lymphoma.
Evaxion Biotech A/S EVAX has secured equity financing of up to $40 million from Lincoln Park Capital Fund.
Evaxion had cash and cash equivalents of $31.4 million at the end of Q1 and expects its cash position, without proceeds from the Agreement, to be sufficient to fund the operations through at least the next 12 months.
Shares are up 5.11% at $1.85 during the premarket trading session.
On The Radar
The Vaccines and Related Biological Products Advisory Committee meeting to discuss Novavax Inc's NVAX emergency use authorization request for its vaccine to prevent COVID-19 in individuals 18 years of age and older.
AIkido Pharma Inc AIKI reverse stock split at a ratio of 1 for 17 effective at 12:01 a.m. ET today.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.